Viking Therapeutics’ GLP-1/GIP drug showed positive results in weight loss in a Phase 2 study. The drug, VK2735, may emerge as a competitor to Eli Lilly’s Zepbound. (Endpoints News)
The Change Healthcare outage extended to a seventh day after a cyber threat actor gained access to its network last week. Parent company UnitedHealth Group said most U.S. pharmacies have set up electronic workarounds to mitigate the impact. (CNBC)
Additionally, the Department of Justice launched an antitrust investigation into UnitedHealth Group. During their interviews, investigators have asked about issues including certain relationships between the company’s UnitedHealthcare insurance unit and its Optum health-services-arm, which owns physician groups, among other assets. (The Wall Street Journal)
The Food and Drug Administration said it will boost the number of inspections at drug manufacturing facilities in India this year, as concerns over drug quality grow. “We are putting every effort into increasing the number of inspections … [and] requesting more drug investigators to be stationed here,” FDA country director for India, Sarah McMullen, said. (Reuters)
The Centers for Disease Control and Prevention director Mandy Cohen told MM+M that the agency is still grappling with rebuilding public trust after its communications blunders during the pandemic. “We must flood the zone with good information,” Cohen said. (MM+M)
Click here to see yesterday’s Five things for pharma marketers to know.